Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins

Journal of the American College of Cardiology

Volumn 68, Issue 20, 2016, Pages 2217-2228

  Kotecha, Dipak ^a   Lam, Carolyn S P ^b   Van Veldhuisen, Dirk J ^c   Van Gelder, Isabelle C ^c   Voors, Adriaan A ^c   Rienstra, Michiel ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

age; diagnosis; epidemiology; natriuretic peptides; outcomes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIARRHYTHMIC AGENT; DIURETIC AGENT; SACUBITRIL PLUS VALSARTAN;

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; PHYSIOLOGY;

ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; HEART FAILURE; HUMANS; PROGNOSIS; STROKE VOLUME;

EID: 85006269470     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.08.048     Document Type: Review

References (101)

1. 1 Vermond, R.A., Geelhoed, B., Verweij, N., et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 66 (2015), 1000–1007.
2. 2 Kelly, J.P., Mentz, R.J., Mebazaa, A., et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 65 (2015), 1668–1682.
3. 3 Kotecha, D., Piccini, J.P., Atrial fibrillation in heart failure: what should we do?. Eur Heart J 36 (2015), 3250–3257.
4. 4 Mamas, M.A., Caldwell, J.C., Chacko, S., et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11 (2009), 676–683.
5. 5 Kotecha, D., Holmes, J., Krum, H., et al., Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384 (2014), 2235–2243.
6. 6 Linssen, G.C., Rienstra, M., Jaarsma, T., et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 13 (2011), 1111–1120.
7. 7 Olsson, L.G., Swedberg, K., Ducharme, A., et al., for the CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006), 1997–2004.
8. 8 Zakeri, R., Borlaug, B.A., McNulty, S.E., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7 (2014), 123–130.
9. 9 Kotecha, D., Chudasama, R., Lane, D.A., et al. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 203 (2016), 660–666.
10. 10 Kirchhof, P., Breithardt, G., Bax, J., et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the Fifth Atrial Fibrillation Network/European Heart Rhythm Association Consensus Conference. Europace 18 (2016), 37–50.
11. 11 Fetsch, T., Bauer, P., Engberding, R., et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25 (2004), 1385–1394.
12. 12 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
13. 13 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37 (2016), 2129–2200.
14. 14 Ho, J.E., Lyass, A., Lee, D.S., et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 6 (2013), 279–286.
15. 15 Santhanakrishnan, R., Wang, N., Larson, M.G., et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 (2016), 484–492.
16. 16 Silva-Cardoso, J., Zharinov, O.J., Ponikowski, P., et al., for the RealiseAF Investigators. Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey. Clin Cardiol 36 (2013), 766–774.
17. 17 Lip, G.Y., Laroche, C., Popescu, M.I., et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail 17 (2015), 570–582.
18. 18 Badheka, A.O., Rathod, A., Kizilbash, M.A., et al. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol 108 (2011), 1283–1288.
19. 19 Mulder, B.A., Van Veldhuisen, D.J., Crijns, H.J., et al., for the RACE II investigators. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 15 (2013), 1311–1318.
20. 20 Benjamin, E.J., Levy, D., Vaziri, S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
21. 21 Fonarow, G.C., Stough, W.G., Abraham, W.T., et al., for the OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
22. 22 Maggioni, A.P., Dahlström, U., Filippatos, G., et al., for the Heart Failure Association of the ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12 (2010), 1076–1084.
23. 23 Maisel, W.H., Stevenson, L.W., Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91 (2003), 2D–8D.
24. 24 Zakeri, R., Chamberlain, A.M., Roger, V.L., et al. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128 (2013), 1085–1093.
25. 25 Mentz, R.J., Kelly, J.P., von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64 (2014), 2281–2293.
26. 26 Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016 Aug 27 [E-pub ahead of print].
27. 27 Redfield, M.M., Jacobsen, S.J., Borlaug, B.A., et al. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112 (2005), 2254–2262.
28. 28 Lam, C.S., Roger, V.L., Rodeheffer, R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115 (2007), 1982–1990.
29. 29 Kawaguchi, M., Hay, I., Fetics, B., et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107 (2003), 714–720.
30. 30 Piccini, J.P., Hammill, B.G., Sinner, M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 5 (2012), 85–93.
31. 31 Tsang, T.S., Gersh, B.J., Appleton, C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40 (2002), 1636–1644.
32. 32 Tsang, T.S., Barnes, M.E., Gersh, B.J., et al. Risks for atrial fibrillation and congestive heart failure in patients ≥65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol 93 (2004), 54–58.
33. 33 Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
34. 34 Lam, C.S.P., Lund, L.H., Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart 102 (2016), 257–259.
35. 35 Frustaci, A., Chimenti, C., Bellocci, F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997), 1180–1184.
36. 36 Sasaki, N., Okumura, Y., Watanabe, I., et al. Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation. J Interv Card Electrophysiol 39 (2014), 241–249.
37. 37 Melenovsky, V., Borlaug, B.A., Rosen, B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49 (2007), 198–207.
38. 38 Knackstedt, C., Gramley, F., Schimpf, T., et al. Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc Pathol 17 (2008), 318–324.
39. 39 Tanaka, K., Zlochiver, S., Vikstrom, K.L., et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 101 (2007), 839–847.
40. 40 Sanders, P., Morton, J.B., Davidson, N.C., et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108 (2003), 1461–1468.
41. 41 Li, D., Melnyk, P., Feng, J., et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101 (2000), 2631–2638.
42. 42 Cha, T.J., Ehrlich, J.R., Zhang, L., et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 109 (2004), 412–418.
43. 43 Yeh, Y.H., Wakili, R., Qi, X.Y., et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1 (2008), 93–102.
44. 44 Hsieh, M.H., Lin, Y.J., Wang, H.H., et al. Functional characterization of atrial electrograms in a pacing-induced heart failure model of atrial fibrillation: importance of regional atrial connexin40 remodeling. J Cardiovasc Electrophysiol 24 (2013), 573–582.
45. 45 Kitzman, D.W., Little, W.C., Brubaker, P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 (2002), 2144–2150.
46. 46 McKie, P.M., Schirger, J.A., Costello-Boerrigter, L.C., et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol 58 (2011), 2095–2103.
47. 47 Casaclang-Verzosa, G., Gersh, B.J., Tsang, T.S., Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51 (2008), 1–11.
48. 48 Manning, W.J., Silverman, D.I., Katz, S.E., et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 23 (1994), 1535–1540.
49. 49 Shite, J., Yokota, Y., Yokoyama, M., Heterogeneity and time course of improvement in cardiac function after cardioversion of chronic atrial fibrillation: assessment of serial echocardiographic indices. Br Heart J 70 (1993), 154–159.
50. 50 Shantsila, E., Shantsila, A., Blann, A.D., et al. Left ventricular fibrosis in atrial fibrillation. Am J Cardiol 111 (2013), 996–1001.
51. 51 Zile, M.R., Baicu, C.F., Ikonomidis, J.S., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
52. 52 Pai, R.G., Varadarajan, P., Tanimoto, M., Effect of atrial fibrillation on the dynamics of mitral annular area. J Heart Valve Dis 12 (2003), 31–37.
53. 53 van den Berg, M.P., van Gelder, I.C., van Veldhuisen, D.J., Depletion of atrial natriuretic peptide during longstanding atrial fibrillation. Europace 6 (2004), 433–437.
54. 54 Ellis, E.R., Josephson, M.E., Heart failure and tachycardia-induced cardiomyopathy. Curr Heart Fail Rep 10 (2013), 296–306.
55. 55 Daoud, E.G., Weiss, R., Bahu, M., et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 78 (1996), 1433–1436.
56. 56 McMurray, J.J.V., Adamopoulos, S., Anker, S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 33 (2012), 1787–1847.
57. 57 Ferrari, R., Böhm, M., Cleland, J.G., et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 17 (2015), 665–671.
58. 58 Basaraba, J.E., Barry, A.R., Pharmacotherapy of heart failure with preserved ejection fraction. Pharmacotherapy 35 (2015), 351–360.
59. 59 Sohn, D.W., Song, J.M., Zo, J.H., et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 12 (1999), 927–931.
60. 60 Sénéchal, M., O'Connor, K., Deblois, J., et al. A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in patients with atrial fibrillation. Echocardiography 25 (2008), 57–63.
61. 61 Kusunose, K., Yamada, H., Nishio, S., et al. Clinical utility of single-beat E/e' obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with preserved systolic function. J Am Coll Cardiol Img 2 (2009), 1147–1156.
62. 62 Li, C., Zhang, J., Zhou, C., Huang, L., et al. Will simultaneous measurement of E/e' index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-valvular atrial fibrillation?. Eur J Echocardiogr 11 (2010), 296–301.
63. 63 Wada, Y., Murata, K., Tanaka, T., et al. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J 76 (2012), 675–681.
64. 64 Okura, H., Takada, Y., Kubo, T., et al. Tissue Doppler-derived index of left ventricular filling pressure, E/E', predicts survival of patients with non-valvular atrial fibrillation. Heart 92 (2006), 1248–1252.
65. 65 Lee, S.H., Jung, J.H., Choi, S.H., et al. Exercise intolerance in patients with atrial fibrillation: clinical and echocardiographic determinants of exercise capacity. J Am Soc Echocardiogr 18 (2005), 1349–1354.
66. 66 Lee, S.H., Choi, S., Chung, W.J., et al. Tissue Doppler index, E/E', and ischemic stroke in patients with atrial fibrillation and preserved left ventricular ejection fraction. J Neurol Sci 271 (2008), 148–152.
67. 67 Punjani, S., Wu, W.C., Cohen, S., et al. Echocardiographic indices of diastolic function relate to functional capacity and quality of life in ambulatory men with atrial fibrillation. J Am Soc Echocardiogr 24 (2011), 533–540.e3.
68. 68 Donal, E., Lip, G.Y., Galderisi, M., et al. EACVI/EHRA expert consensus document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 17 (2016), 355–383.
69. 69 Santos, A.B., Kraigher-Krainer, E., Gupta, D.K., et al., for the PARAMOUNT Investigators. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail 16 (2014), 1096–1103.
70. 70 Nagueh, S.F., Appleton, C.P., Gillebert, T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10 (2009), 165–193.
71. 71 Oluleye, O.W., Rector, T.S., Win, S., et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail 7 (2014), 960–966.
72. 72 Lam, C.S., Carson, P.E., Anand, I.S., et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 5 (2012), 571–578.
73. 73 Fung, J.W., Sanderson, J.E., Yip, G.W., et al. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Card Fail 13 (2007), 649–655.
74. 74 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), 2246–2280.
75. 75 Cleland, J.G., Tendera, M., Adamus, J., et al., for the PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006), 2338–2345.
76. 76 Massie, B.M., Carson, P.E., McMurray, J.J., et al., for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
77. 77 Yusuf, S., Pfeffer, M.A., Swedberg, K., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
78. 78 Ziff, O.J., Lane, D.A., Samra, M., et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, 351, 2015, h4451.
79. 79 Sandhu, R.K., Hohnloser, S.H., Pfeffer, M.A., et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke 46 (2015), 667–672.
80. 80 Kotecha, D., Banerjee, A., Lip, G.Y., Increased stroke risk in atrial fibrillation patients with heart failure: does ejection fraction matter?. Stroke 46 (2015), 608–609.
81. 81 Xiong, Q., Lau, Y.C., Senoo, K., et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 17 (2015), 1192–1200.
82. 82 Abed, H.S., Wittert, G.A., Leong, D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310 (2013), 2050–2060.
83. 83 Pathak, R.K., Middeldorp, M.E., Meredith, M., et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
84. 84 Pathak, R.K., Middeldorp, M.E., Lau, D.H., et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64 (2014), 2222–2231.
85. 85 Pathak, R.K., Elliott, A., Middeldorp, M.E., et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT Study. J Am Coll Cardiol 66 (2015), 985–996.
86. 86 Kitzman, D.W., Brubaker, P., Morgan, T., et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315 (2016), 36–46.
87. 87 University of Birmingham. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02391337. Accessed August 29, 2016.
88. 88 Groenveld, H.F., Crijns, H.J.G.M., Van den Berg, M.P., et al., for the RACE II Investigators. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) Study. J Am Coll Cardiol 58 (2011), 1795–1803.
89. 89 Grönefeld, G.C., Lilienthal, J., Kuck, K.H., et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Eur Heart J 24 (2003), 1430–1436.
90. 90 Machino-Ohtsuka, T., Seo, Y., Ishizu, T., et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 62 (2013), 1857–1865.
91. 91 Aliot, E., Brandes, A., Eckardt, L., et al. The EAST study: redefining the role of rhythm control therapy in atrial fibrillation. Eur Heart J 36 (2015), 255–256.
92. 92 Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. J Am Coll Cardiol HF 2 (2014), 97–112.
93. 93 Solomon, S.D., Zile, M., Pieske, B., et al., for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
94. 94 McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
95. 95 Chan, M.M., Lam, C.S., How do patients with heart failure with preserved ejection fraction die?. Eur J Heart Fail 15 (2013), 604–613.
96. 96 Adabag, S., Rector, T.S., Anand, I.S., et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 16 (2014), 1175–1182.
97. 97 University Medical Center Groningen. Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction (VIP-HF). ClinicalTrials.gov. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01989299. Accessed August 29, 2016.
98. 98 Hai, O.Y., Mentz, R.J., Zannad, F., et al. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. Eur J Heart Fail 17 (2015), 135–143.
99. 99 Menet, A., Greffe, L., Ennezat, P.V., et al. Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction?. Am Heart J 168 (2014), 909–916.e1.
100. 100 Rosenberg, M.A., Manning, W.J., Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 126 (2012), 2353–2362.
101. 101 Adamson, P.B., Abraham, W.T., Bourge, R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7 (2014), 935–944.